← All indications
Peripheral Arterial Disease
Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.
Subtype terms (2)
More specific conditions that are subtypes of Peripheral Arterial Disease in the MeSH hierarchy.
- Chronic Limb-Threatening Ischemia
73 drugs (27 approved, 46 experimental)
- Intermittent Claudication
59 drugs (27 approved, 32 experimental)
Drugs by status
Approved for this indication (4)
Phase 4 trials (37)
- simvastatin
- ezetimibe
- allopurinol
- vitamin d3
- heparin
- methylprednisolone
- urea
- prednisone
- gadobutrol
- gadoteric acid
- paclitaxel
- liraglutide
- amlodipine
- rosuvastatin
- iloprost
- levocarnitine
- niacin
- olmesartan
- evolocumab
- atorvastatin
- ticagrelor
- pravastatin
- ranolazine
- alirocumab
- sitagliptin
- sapropterin
- sarpogrelate
- acetylsalicylic acid
- bupivacaine
- enoxaparin
- +7 more
Phase 3 trials (30)
- montelukast
- beetroot juice
- captopril
- temsirolimus
- laropiprant
- ibuprofen
- Lumbricus rubellus
- bovine colostrum
- icosapent ethyl
- nebivolol
- colchicine
- propionyl l-carnitine
- semaglutide
- snf472
- resveratrol
- sulodexide
- nicotinamide
- allogeneic adipose derived mesenchymal stem cell
- flax
- nl003
- rexmyelocel-t
- ayurvedic suved
- metoprolol
- sodium thiosulfate
- sildenafil
- phenylpropanolamine
- ticlopidine
- cocoa flavanols
- ly3502970
- calf serum
Phase 2 trials (58)
- edoxaban
- sodium nitrate
- sodium nitrite
- perfluorobutane
- canakinumab
- l-carnosine
- cocoa bean
- dark chocolate
- dvc1-0101
- probucol
- trametinib
- bone marrow derived mesenchymal stem cells
- indocyanine green
- jvrs-100
- citrulline
- platelet-rich plasma
- gadopenteate dimeglumine
- valsartan
- acetaminophen
- pvs-10200
- salvianolate
- stem cells
- tirasemtiv
- alteplase
- urokinase
- ferumoxytol
- cellulose
- alprostadil
- zibotentan
- ald-301
- +28 more
Phase 1 trials (23)
- nitroglycerin
- acetylcysteine
- biwh 3
- esmolol
- fgf-1
- gadofosveset trisodium
- autologous cd133+ stem cells
- pegulicianine
- vitamin c
- allogeneic hematopoietic stem cells
- angiotensin 1-7
- vonapanitase
- autologous mesenchymal stem cell-derived neural progenitors
- autologous mononuclear stem cell
- losartan
- pioglitazone
- pyridoxine
- edetic acid
- inclacumab
- fludeoxyglucose f-18
- sev-hfgf2/df
- autologous adipose-derived mesenchymal stem cells
- tetrahydrobiopterin
Other trials (39)
- autologous blood
- bosentan
- coconut oil
- oxycodone
- egg
- ganirelix
- cyanocobalamin
- nevulose
- soybean oil
- magnesium oxide
- oleic acid
- dipyridamole
- platelets
- safflower oil
- sirolimus
- sorbitol
- estradiol
- calcitriol
- bamboo leaves
- arthrospira platensis
- l-epigallocatechin
- zinc dichloride
- amniotic stem cells
- hydrochlorothiazide
- pregabalin
- hawthorn berry extract
- telmisartan
- lactic acid
- l-nmma
- lisinopril
- +9 more
Organizations
Organization Involved with Phase 4 Indications (77)
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Bracco
- Guerbet
- Pfizer
- Kobe University
- Mercator MedSystems, Inc.
- Mochida Pharmaceutical Company, Ltd.
- Otsuka
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Roma La Sapienza
- Arteriogenesis Competence Network
- Barnsley Hospital
- Baylor University
- Cathay General Hospital
- Changhua Christian Hospital
- Chung Shan Medical University
- Chimei Medical Center
- Harvard University
- University of Washington
- Hoosier Cancer Research Network
- Hospital Universitario Getafe
- Kaohsiung Medical University
- Kuang Tien General Hospital
- LifeBridge Health
- Los Angeles Biomedical Research Institute
- Monash University
- National Cheng Kung University
- Northwestern University
- +47 more
Organization Involved with Phase 3 Indications (69)
- Takeda
- United Therapeutics
- Forest Laboratories
- Roche
- Novo Nordisk
- Anesiva, Inc.
- Bayer
- Beijing Northland Biotech. Co., Ltd.
- Boston Scientific Corporation
- Kos Pharmaceuticals
- Leadiant Biosciences, Inc.
- Ixaka
- Omrix Biopharmaceuticals, Inc.
- Alvogen
- Dexa Medica Group
- Ethicon
- ZonMw: The Netherlands Organisation for Health Research and Development
- Anand, Sonia, M.D.
- University of Manitoba
- University of Pittsburgh
- American Heart Association
- Brown University
- Case Western Reserve University
- Dartmouth University
- Hospital do Coracao
- Human Stem Cell Institute, Russia
- McMaster University
- Nanjing Medical University
- Ochsner Health System
- Rhode Island Hospital
- +39 more
Organization Involved with Phase 2 Indications (96)
- Biomarin
- Daiichi Sankyo
- Medistem
- Celgene
- Shire
- Genzyme
- Arca Biopharma, Inc.
- Novartis
- Aldagen
- Angiogenix
- Apceth GmbH & Co. KG
- Baxalta
- BioGenCell Ltd.
- Biopure Corporation
- Endovasc
- FGK Clinical Research GmbH
- GlaxoSmithKline
- Juventas Therapeutics, Inc.
- MultiGene Vascular Systems Ltd.
- Nissan Chemical Industries
- Pluristem Ltd.
- Reven Pharmaceuticals, Inc.
- Rheacell GmbH & Co. KG
- Polysan, Ltd.
- TheraVasc Inc.
- TheraVitae Ltd.
- Valentis
- Vericel Corporation
- Cytokinetics
- TCA Cellular Therapy
- +66 more
Organization Involved with Phase 1 Indications (16)
- Venturis Therapeutics
- Proteon Therapeutics
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- ev3
- Boehringer Ingelheim
- ReNeuron Limited
- Huazhong University of Science and Technology
- Mt. Sinai Medical Center, Miami
- South China Research Center for Stem Cell and Regenerative Medicine
- Affiliated Hospital of Military Medical Sciences
- Southern Medical University
- Humboldt University
- Washington University in St. Louis
- Foxhollow Technologies
- People's Liberation Army of China
- Deborah Heart and Lung Center
Organization Involved with Other Experimental Indications (27)
- HumanN
- Balton Sp.zo.o.
- Midwest Cardiovascular Research Foundation
- United States Army
- Maastricht University
- Boston University
- Chang Gung University
- Gottfried Wilhelm Leibniz Universität Hannover
- Medical College of Wisconsin
- Sanford Health
- St. John's Research Institute
- University of Iowa
- University of Limerick
- University of Oklahoma
- University of Rome Tor Vergata
- University of Toronto
- Mayo Clinic
- University of Cambridge
- University of Angers
- Methodist Cancer Center, Houston, Texas
- University of Brescia
- National Health and Medical Research Council, Australia
- Clinical Trial Center Maastricht
- American Heart of Poland
- Spectranetics Corporation
- Cambridge Theranostics Ltd
- Reliant Pharmaceuticals